Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Capitol Capsule: Regulatory, Legislative, Legal and Political Biopharma News

This article was originally published in Scrip

Executive Summary

This past week in US regulatory, legislative, legal and political news affecting the biopharmaceutical industry included new insight into how President Barack Obama's nominee to lead the FDA, Robert Califf, would run the agency and additional questions raised ahead of his confirmation by the Republican and Democratic leaders of the Senate Health Committee; Apotex Inc.'s strategy for winning a lawsuit involving its pegfilgrastim biosimilar brought by Amgen Inc., plus how supporters of the former company think the US Court of Appeals for the Federal Circuit should rule in the case; and the move by Valeant Pharmaceuticals International Inc., which is under investigation by federal prosecutors and Capitol Hill lawmakers, to substitute Howard Schiller for ailing CEO Michael Pearson; plus other Washington news.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC064169

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel